People with trisomy 21, or Down syndrome, have a significantly elevated risk for keratoconus, with many reports citing a 30% prevalence of keratoconus in this population.
There has been a sea change in the care of patients with keratoconus in the U.S. since the FDA approval of iLink corneal collagen cross-linking in 2016.